Hypocomplementemia in systemic sclerosis - Clinical and serological correlations

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2218-2223

  Hudson, Marie ^a   Walker, Jennifer G ^b   Fritzler, Marvin ^b   Taillefer, Suzanne ^a   Baron, Murray ^a   Abu Hakima, M ^c   Docherty, P ^c   Dunne, J ^c   Jones, N ^c   Khalidi, N ^c   LeClercq, S ^c   Markland, J ^c   Mathieu, J P ^c   Pope, J ^c   Rahman, P ^c   Robinson, D ^c   Smith, D ^c   Sutton, E ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c SMBD Jewish General Hospital ^*

Author keywords

Autoimmune disease; Classification; Complements; Scleroderma

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CHROMATIN; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; COMPLEMENT BLOOD LEVEL; COMPLEMENT FIXATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PATHOGENESIS; PRIORITY JOURNAL; SCLERODERMA; SERODIAGNOSIS; SYSTEMIC SCLEROSIS; VASCULITIS;

ADULT; AGED; AUTOANTIBODIES; CANADA; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SCLERODERMA, SYSTEMIC;

EID: 35948936833     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Seibold J. Scleroderma. In: Harris E, Budd RC, Firestein GS, et al, editors. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier; 2005.
2. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
3. Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996;39:1035-40.
4. Matsuura E, Ohta A, Kanegae F, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003;30:1782-7.
5. Taillefer S, Baron M, Hudson M, and the Canadian Scleroderma Research Group. Preliminary study of the predictors of depressive symptoms in patients with systemic sclerosis (SSc) [abstract]. Vienna: EULAR; 2005.
6. Danieli E, Airo P, Bettoni L, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005;24:48-54.
7. Del Rosso A, Boldrini M, D'Agostino D, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004;51:475-81.
8. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
9. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
11. Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum 1989;32:1262-7.
12. Valentini G, Delia Rossa A, Bombardiert S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
13. Van Tubergen A, Debats I, Ryser L, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 2002;47:242-8.
14. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990;17:1022-4.
15. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
16. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
17. Radloff LS, Locke BZ. Community surveys of psychiatric disorders. In: Weisman NM, Myers JK, Ross CE, editors. The Community Mental Health Assessment Surveys and the CES-D scale. New Brunswick, NJ: Rutgers University Press; 1986.
18. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
19. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
20. Reading AE. The McGill Pain Questionnaire: an appraisal. In: Melzack R, editor. Pain measurement and assessment. New York: Raven Press; 1983:55-61.
21. Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
22. Ware JJ, Snow K, Kosinski M, Gandek B. SF-36 Health Survey: Manual and interpretation guide. Boston: The Health Institute, New England Medical Cente; 1993.
23. Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
24. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
25. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21 Suppl 29:S42-6.
26. Medical Research Council. Aids to the examination of the peripheral nervous system. In: Memorandum no. 45. London: Her Majesty's Stationery Office; 1976.
27. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
28. Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev 2002;1:321-8.
29. Suer W, Dahnrich C, Schlumberger W, Stocker W. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J Autoimmun 2004;22:325-34.
30. Bizzaro N, Tonutti E, Villalata D, et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Sc170) autoantibodies: Results of a multicenter study. Clin Chem 2000;46:1681-5.
31. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997;103:242-8.
32. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49:399-412.
33. Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A. Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 2006;25:542-3.
34. Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:376-83.
35. Rubin RL, Teodorescu M, Beutner EH, Plunkett RW. Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus. Lupus 2004;13:249-56.
36. Fritzler MJ, McCarty GA, Ryan JP, Kinsella TD. Clinical features of patients with antibodies directed against proliferating cell nuclear antigen. Arthritis Rheum 1983;26:140-5.
37. Martin L, Pauls JD, Ryan JP, Fritzler MJ. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone. Ann Rheum Dis 1993;52:780-4.
38. Hu PQ, Fertig N, Medsger TA, Wright TA. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003;48:1363-73.
39. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
40. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.
41. Genth E, Hunzelmann N, Krieg T, et al. The German network for systemic scleroderma: establishment of a register encompassing 1350 patients leading to new data on organ involvement and immuno suppressive therapy [abstract]. Scleroderma Care Res 2006;4:33-4.
42. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32:584-93.
43. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
44. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
45. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
46. Rodriguez-Reyna TS, Alarcon-Segovia D. The different faces of shared autoimmunity. Autoimmun Rev 2006;5:86-8.
47. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004;10:CR615-21.
48. Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol 2002;16:807-16.